Dimitris Voliotis net worth and biography

Dimitris Voliotis Biography and Net Worth

Dimitris is Senior Vice President of Clinical Development at Zentalis Pharmaceuticals and serves as Head of Global Clinical Development. Prior to joining Zentalis, he was CureVac AG’s Chief Development Officer overseeing preclinical and clinical development activities for oncology, rare diseases/molecular therapies and prophylactic vaccines. Previously, he was Global Head of Clinical Development Oncology at Eisai Inc. overseeing the early and late stage development pipeline in the Oncology Business Unit. He has worked on clinical development projects in all trial phases from preclinical-clinical transition through phases 1 to 3 and has overseen numerous regulatory filings for Nexavar®, Xofigo® as well as Halaven® and Lenvima®. Dimitris first joined the pharmaceutical industry with Bayer HealthCare in 2001 at the Institute of Clinical Pharmacology in Wuppertal, Germany. He was responsible for a number of oncology projects in early development stages and served as Medical Expert, Oncology Expert and Global Clinical Pharmacology Project Leader. As Global Clinical Leader Oncology at Bayer, he was responsible for numerous compounds in different stages and for multiple indications before becoming a Vice President and Oncology Group Head, coordinating the clinical development for Nexavar® and Xofigo®. He is board certified in Internal Medicine, Medical Oncology and Hematology and served as a Senior Consultant in Oncology and Head, Laboratory for Diagnostic Hematology and Immunohematology at the Medical Clinic, University of Cologne, Germany. Dimitris received his medical degree from Cologne University Medical School. He completed his doctoral thesis in experimental oncology research and undertook clinical training in Internal Medicine, Immunology, Oncology and Hematology at the Medical Clinic, University of Cologne, while continuing his clinical research in hematological and solid tumour malignancies as well as experimental and clinical cell cytometry.

Interesting Fact: Dimitris is half German, half Greek, speaks three languages (plus understands two dialects: Bavarian and Kölsch), and has lived in both Germany and Greece before moving to the US. Following this transatlantic relocation to New Jersey, he became a NY Jets fan, without initially realizing what exactly he was getting himself into. J-E-T-S!

How do I contact Dimitris Voliotis?

The corporate mailing address for Dr. Voliotis and other Zentalis Pharmaceuticals executives is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. Zentalis Pharmaceuticals can also be reached via phone at 212-433-3791 and via email at [email protected] Learn More on Dimitris Voliotis' contact information.

Has Dimitris Voliotis been buying or selling shares of Zentalis Pharmaceuticals?

Dimitris Voliotis has not been actively trading shares of Zentalis Pharmaceuticals over the course of the past ninety days. Most recently, Dimitris Voliotis sold 601 shares of the business's stock in a transaction on Monday, February 14th. The shares were sold at an average price of $50.23, for a transaction totalling $30,188.23. Learn More on Dimitris Voliotis' trading history.

Who are Zentalis Pharmaceuticals' active insiders?

Zentalis Pharmaceuticals' insider roster includes Kimberly Blackwell (Director), Kevin Bunker (COO), Melissa Epperly (CFO), Cam Gallagher (Director), David Johnson (Director), Alexis Pinto (Insider), Anthony Sun (CEO), and Dimitris Voliotis (SVP). Learn More on Zentalis Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Zentalis Pharmaceuticals?

In the last twelve months, insiders at the sold shares 28 times. They sold a total of 257,046 shares worth more than $9,798,239.64. The most recent insider tranaction occured on January, 17th when President Cam Gallagher sold 10,000 shares worth more than $241,500.00. Insiders at Zentalis Pharmaceuticals own 19.9% of the company. Learn More about insider trades at Zentalis Pharmaceuticals.

Information on this page was last updated on 1/17/2023.

Dimitris Voliotis Insider Trading History at Zentalis Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/14/2022Sell601$50.23$30,188.23View SEC Filing Icon  
1/20/2022Sell10,000$60.63$606,300.00View SEC Filing Icon  
See Full Table

Dimitris Voliotis Buying and Selling Activity at Zentalis Pharmaceuticals

This chart shows Dimitris Voliotis's buying and selling at Zentalis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Zentalis Pharmaceuticals Company Overview

Zentalis Pharmaceuticals logo
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Read More

Today's Range

Now: $23.29
Low: $22.94
High: $24.43

50 Day Range

MA: $21.17
Low: $18.07
High: $24.94

2 Week Range

Now: $23.29
Low: $17.33
High: $55.42


353,683 shs

Average Volume

531,366 shs

Market Capitalization

$1.33 billion

P/E Ratio


Dividend Yield